Latest ACUTA CAPITAL PARTNERS, LLC Stock Portfolio
$118Million– No. of Holdings #32
ACUTA CAPITAL PARTNERS, LLC Performance:
2024 Q2: -9.71%YTD: 15.3%2023: 7.39%
Performance for 2024 Q2 is -9.71%, and YTD is 15.3%, and 2023 is 7.39%.
About ACUTA CAPITAL PARTNERS, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, ACUTA CAPITAL PARTNERS, LLC reported an equity portfolio of $118.7 Millions as of 30 Jun, 2024.
The top stock holdings of ACUTA CAPITAL PARTNERS, LLC are OCUL, , PCVX. The fund has invested 16% of it's portfolio in OCULAR THERAPEUTIX INC and 7.8% of portfolio in ENLIVEN THERAPEUTICS INC.
The fund managers got completely rid off APPLIED THERAPEUTICS INC (APLT), DISC MEDICINE INC and CELLDEX THERAPEUTICS INC (CLDX) stocks. They significantly reduced their stock positions in SAREPTA THERAPEUTICS INC (SRPT), CELLECTAR BIOSCIENCES INC. (CLRB) and LEAP THERAPEUTICS INC (LPTX). ACUTA CAPITAL PARTNERS, LLC opened new stock positions in CORBUS PHARMACEUTICALS HOLDI (CRBP), HELIX ACQUISITION CORP II and TREVI THERAPEUTICS INC (TRVI). The fund showed a lot of confidence in some stocks as they added substantially to KURA ONCOLOGY INC. COMMON STOCK (KURA), CRINETICS PHARMACEUTICALS (CRNX) and MEREO BIOPHARMA GROUP PL-ADR (MREO).
The top stock holdings of ACUTA CAPITAL PARTNERS, LLC are OCUL, , PCVX. The fund has invested 16% of it's portfolio in OCULAR THERAPEUTIX INC and 7.8% of portfolio in ENLIVEN THERAPEUTICS INC.
The fund managers got completely rid off APPLIED THERAPEUTICS INC (APLT), DISC MEDICINE INC and CELLDEX THERAPEUTICS INC (CLDX) stocks. They significantly reduced their stock positions in SAREPTA THERAPEUTICS INC (SRPT), CELLECTAR BIOSCIENCES INC. (CLRB) and LEAP THERAPEUTICS INC (LPTX). ACUTA CAPITAL PARTNERS, LLC opened new stock positions in CORBUS PHARMACEUTICALS HOLDI (CRBP), HELIX ACQUISITION CORP II and TREVI THERAPEUTICS INC (TRVI). The fund showed a lot of confidence in some stocks as they added substantially to KURA ONCOLOGY INC. COMMON STOCK (KURA), CRINETICS PHARMACEUTICALS (CRNX) and MEREO BIOPHARMA GROUP PL-ADR (MREO).
ACUTA CAPITAL PARTNERS, LLC Equity Portfolio Value
Last Reported on: 14 Aug, 2024
ACUTA CAPITAL PARTNERS, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that ACUTA CAPITAL PARTNERS, LLC made a return of -9.71% in the last quarter. In trailing 12 months, it's portfolio return was 22.34%.
New Buys
| Ticker | $ Bought |
|---|---|
| corbus pharmaceuticals holdi | 2,918,620 |
| helix acquisition corp ii | 1,817,480 |
| argenx se | 1,720,160 |
| trevi therapeutics inc | 774,800 |
| celcuity inc | 737,100 |
| pliant therapeutics inc | 496,650 |
| rapport therapeutics inc | 465,200 |
| newamsterdam pharma co nv | 432,225 |
New stocks bought by ACUTA CAPITAL PARTNERS, LLC
Additions
| Ticker | % Inc. |
|---|---|
| kura oncology inc. common stock | 81.11 |
| crinetics pharmaceuticals | 72.37 |
| mereo biopharma group pl-adr | 70.15 |
| agios pharma | 42.41 |
| arcellx inc | 22.32 |
| insmed inc | 16.82 |
| dyne therapeutics inc | 15.18 |
| vaxcyte inc | 5.31 |
Additions to existing portfolio by ACUTA CAPITAL PARTNERS, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| sarepta therapeutics inc | -57.14 |
| cellectar biosciences inc. | -50.87 |
| leap therapeutics inc | -44.94 |
| taysha gene therapies inc | -30.07 |
| rocket pharmaceuticals inc | -23.38 |
| mersana therapeutics inc | -23.17 |
| terns pharmaceuticals inc | -20.6 |
| oric pharmaceuticals inc | -7.69 |
ACUTA CAPITAL PARTNERS, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| applied therapeutics inc | -5,385,600 |
| hillevax inc | -4,167,630 |
| verastem inc | -2,443,720 |
| lyra therapeutics inc | -1,078,050 |
| celldex therapeutics inc | -4,574,730 |
| immunovant inc | -2,983,700 |
| disc medicine inc | -4,781,570 |
| ultragenyx pharmaceutical inc | -933,800 |
ACUTA CAPITAL PARTNERS, LLC got rid off the above stocks
Sector Distribution
ACUTA CAPITAL PARTNERS, LLC has about 85.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 85.9 |
| Others | 14.1 |
Market Cap. Distribution
ACUTA CAPITAL PARTNERS, LLC has about 7.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 41.9 |
| MID-CAP | 27.6 |
| UNALLOCATED | 16.5 |
| LARGE-CAP | 7.7 |
| MICRO-CAP | 3.9 |
| NANO-CAP | 2.3 |
Stocks belong to which Index?
About 66.7% of the stocks held by ACUTA CAPITAL PARTNERS, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 66.7 |
| Others | 33.3 |
ACUTA CAPITAL PARTNERS, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of ACUTA CAPITAL PARTNERS, LLC
ACUTA CAPITAL PARTNERS, LLC has 32 stocks in it's portfolio. About 65.3% of the portfolio is in top 10 stocks. OCUL proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for ACUTA CAPITAL PARTNERS, LLC last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AADI | aadi biosciences inc | 2.27 | 1,849,400 | 2,700,130 | unchanged | 0.00 | ||
| ACLX | arcellx inc | 1.96 | 42,200 | 2,329,020 | added | 22.32 | ||
| AGIO | agios pharma | 2.86 | 78,700 | 3,393,540 | added | 42.41 | ||
| APLT | applied therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CELC | celcuity inc | 0.62 | 45,000 | 737,100 | new | |||
| CLDX | celldex therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CLRB | cellectar biosciences inc. | 0.15 | 70,500 | 176,250 | reduced | -50.87 | ||
| CRBP | corbus pharmaceuticals holdi | 2.46 | 64,500 | 2,918,620 | new | |||
| CRNX | crinetics pharmaceuticals | 5.10 | 135,141 | 6,052,960 | added | 72.37 | ||
| DYN | dyne therapeutics inc | 6.32 | 212,500 | 7,499,120 | added | 15.18 | ||
| HLVX | hillevax inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IMVT | immunovant inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| INSM | insmed inc | 4.07 | 72,100 | 4,830,700 | added | 16.82 | ||
| ITCI | intra-cellular therapies inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KURA | kura oncology inc. common stock | 2.83 | 163,000 | 3,356,170 | added | 81.11 | ||
| LPTX | leap therapeutics inc | 0.32 | 195,000 | 382,200 | reduced | -44.94 | ||
| LYRA | lyra therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MREO | mereo biopharma group pl-adr | 2.05 | 677,000 | 2,437,200 | added | 70.15 | ||
| MRSN | mersana therapeutics inc | 2.82 | 1,663,000 | 3,342,630 | reduced | -23.17 | ||
| NAMS | newamsterdam pharma co nv | 0.36 | 22,500 | 432,225 | new | |||